145 results on '"Saiki H"'
Search Results
2. Effect of lap-sheets on deep drawing of metallic foil cups
- Author
-
Marumo, Y., Saiki, H., and Onoue, A.
- Published
- 2001
- Full Text
- View/download PDF
3. Effects of lap sheets on the improvement of the formability of metal foil
- Author
-
Marumo, Y, Saiki, H, and Onoue, A
- Published
- 2001
- Full Text
- View/download PDF
4. Electrochemical Concentration of Aqueous [18F]Fluoride into an Aprotic Solvent in a Disposable Microfluidic Cell
- Author
-
Saiki, H., Iwata, R., Wong, R., Furumoto, S., Ishikawa, Y., Nakanishi, H., and Ozeki, E.
- Published
- 2008
5. Microfluidic Radiofluorination Using Electrochemically Concentrated [18F]Fluoride
- Author
-
Wong, R., Iwata, R., Furumoto, S., Saiki, H., Ishikawa, Y., and Ozeki, E.
- Published
- 2011
6. 457P Background of patients (pts) with ALK rearranged (ALK+) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
- Author
-
Ito, K., primary, Saiki, H., additional, Sakaguchi, T., additional, Hayashi, K., additional, Nishii, Y., additional, Watanabe, F., additional, Hataji, O., additional, Okano, T., additional, Naito, M., additional, Ibata, H., additional, Fujiwara, A., additional, Yoshida, M., additional, Itani, H., additional, Tanigawa, M., additional, and Kobayashi, H., additional
- Published
- 2015
- Full Text
- View/download PDF
7. Abstracts of the Seventeenth Annual Meeting of the Japanese Society of Biometeorology, Osaka, 21–22 November 1978
- Author
-
Iriki, M., Kozawa, E., Iguchi, T., Hori, T., Tsuzuki, S., Tsunashima, K., Kubo, K., Kawakami, M., Murakami, N., Tokura, H., Suzuki, T., Yoshimura, C., Tsurutani, T., Ogawa, T., Ito, M., Miyagawa, T., Asayama, M., Nagasaka, T., Hirata, K., Sugano, Y., Shibata, H., Mohri, M., Sasaki, T., Chiba, Y., Osada, H., Sakaguchi, E., Yurugi, R., Yamaoka, S., Hiroshige, T., Honma, K., Itoh, S., Hirokawa, Y., Horie, G., Nakamura, S., Tsukamoto, N., Watanabe, M., Sohn, J. Y., Isoda, N., Kobayashi, Y., Yamaguchi, K., Nishimura, K., Kawashima, Y., Gotoh, S., Watanabe, T., Matsumoto, Y., Kawahara, Y., Hoshiai, T., Minamino, O., Ota, K., Inoue, T., Naruse, T., Kajii, H., Inaba, K., Miyano, A., Kamiyama, K., Kito, K., Nemoto, O., Horikoshi, T., Namihira, G., Saiki, H., Saiki, M., Nakaya, M., Sudoh, M., Abe, M., Nakahara, H., Yokoyama, H., Ohara, K., Okuda, N., Kuroshima, A., Kurahashi, M., Yahata, T., Doi, K., Ohno, T., Agishi, Y., Moriya, K., Yamaguchi, T., Ueda, G., Takeoka, M., Koshihara, Y., Tanaka, N., Tsujita, J., Mayuzumi, M., Itoh, K. B., Hori, S., Nakamura, M., Yukawa, K., Hirata, H., Ikeda, T., Ishihara, U., Morimoto, T., Miki, K., Shiraki, K., Niwa, K., Ohnuki, Y., Nakayama, T., Igawa, S., Yorimoto, A., Kita, H., Hanawa, K., Sugiyama, M., Iwami, K., Hayashi, O., Fujita, K., Kikuchi, M., Matsushita, K., Tsujino, A., Araki, T., Toda, Y., Tochihara, T., Ohnaka, T., Matsui, J., Tanaka, M., Yoshida, K., Yokoi, T., Yanaga, T., Kaji, M., Sato, T., Momiyama, M. S., Fujii, Y., Murakami, M., Ichimaru, Y., Yoshiyama, T., Asahina, K., Watanabe, K., Sekiguchi, N., Matsumoto, T., Mori, K., Yano, T., Katayama, K., Shimura, M., and Miura, T.
- Published
- 1981
- Full Text
- View/download PDF
8. P06.11: Twin–twin transfusion syndrome followed by the recipient intrauterine fetal death and the donor right heart failure after selective fetoscopic laser photo‐coagulation: a case report
- Author
-
Kiyoshi, K., primary, Makishi, A., additional, Shiro, M., additional, Maesawa, Y., additional, Sasahara, J., additional, Sasaki, H., additional, Takamatsu, Y., additional, Tanaka, T., additional, Samoto, T., additional, Saiki, H., additional, Kido, S., additional, Ishii, K., additional, Murakoshi, T., additional, and Funakoshi, T., additional
- Published
- 2010
- Full Text
- View/download PDF
9. Assessment of Technologies for Reducing CO2 Emission
- Author
-
Kaya, Y., Fujii, Y., Matsuhashi, R., Furugaki, I., Yamaji, K., Kobayaski, O., Shindo, Y., Saiki, H., Kaya, Y., Fujii, Y., Matsuhashi, R., Furugaki, I., Yamaji, K., Kobayaski, O., Shindo, Y., and Saiki, H.
- Abstract
There are a wide variety of technologies for reducing CO2 emissions, of which a greater part are those of energy technologies. The paper aims at assessing these technologies with regional differences of technology characteristics taken into account. The first part examines merits and demerits of individual technology, and thus envisages its possible future. The second part describes a global energy model, which generates comprehensive long term future scenarios of energy and CO2 emission in various regions of the world.
- Published
- 1993
10. Immunocytochemical Localization of Phenylalanine Ammonia-Lyase and Cinnamyl Alcohol Dehydrogenase in Differentiating Tracheary Elements Derived from Zinnia Mesophyll Cells
- Author
-
Nakashima, J., primary, Awano, T., additional, Takabe, K., additional, Fujita, M., additional, and Saiki, H., additional
- Published
- 1997
- Full Text
- View/download PDF
11. Direct Visualization of Lignifying Secondary Wall Thickenings in Zinnia elegansCells in Culture
- Author
-
Nakashima, J., primary, Mizuno, T., additional, Takabe, K., additional, Fujita, M., additional, and Saiki, H., additional
- Published
- 1997
- Full Text
- View/download PDF
12. Nitrogen removal by tubular gel containing Nitrosomonas europaea and Paracoccus denitrificans
- Author
-
Uemoto, H, primary and Saiki, H, additional
- Published
- 1996
- Full Text
- View/download PDF
13. The absence of Pmp47, a putative yeast peroxisomal transporter, causes a defect in transport and folding of a specific matrix enzyme.
- Author
-
Sakai, Y, primary, Saiganji, A, additional, Yurimoto, H, additional, Takabe, K, additional, Saiki, H, additional, and Kato, N, additional
- Published
- 1996
- Full Text
- View/download PDF
14. The Candida boidinii peroxisomal membrane protein Pmp30 has a role in peroxisomal proliferation and is functionally homologous to Pmp27 from Saccharomyces cerevisiae
- Author
-
Sakai, Y, primary, Marshall, P A, additional, Saiganji, A, additional, Takabe, K, additional, Saiki, H, additional, Kato, N, additional, and Goodman, J M, additional
- Published
- 1995
- Full Text
- View/download PDF
15. Zonal distribution of cysteine uptake in the perfused rat liver.
- Author
-
Saiki, H, primary, Chan, E T, additional, Wong, E, additional, Yamamuro, W, additional, Ookhtens, M, additional, and Kaplowitz, N, additional
- Published
- 1992
- Full Text
- View/download PDF
16. Interactions between a tetraanionic porphyrin and the methylviologen dication in methanol studied by fluorescence quenching reaction
- Author
-
Pant, S., Ohtaka-Saiki, H., Takezaki, M., and Tominaga, T.
- Published
- 2001
- Full Text
- View/download PDF
17. Effect of the surface structure on the resistance to plastic deformation of a hot forging tool
- Author
-
Saiki, H., Marumo, Y., Minami, A., and Sonoi, T.
- Published
- 2001
- Full Text
- View/download PDF
18. Mutual and tracer diffusion coefficients for zwitterionic and ionic mixed micellar systems: effects of counter ions and micellar aggregation numbers
- Author
-
Nogami, Y., Watanabe, H., Ohtaka-Saiki, H., and Tominaga, T.
- Published
- 2000
- Full Text
- View/download PDF
19. Preparation of spatially ordered multilayer thin films of antibody and their binding properties
- Author
-
Hoshi, T., Saiki, H., and Anzai, J. I.
- Published
- 2000
- Full Text
- View/download PDF
20. Hole flanging with ironing of two-ply thick sheet metals
- Author
-
Kumagai, T., Saiki, H., and Meng, Y.
- Published
- 1999
- Full Text
- View/download PDF
21. Combined effects of strain hardening characteristics and tool geometry on the deep-drawability of square aluminum cups
- Author
-
Marumo, Y., Saiki, H., and Mori, T.
- Published
- 1999
- Full Text
- View/download PDF
22. Desulphurisation of coal by microbial flotation in a semicontinuous system.
- Author
-
Nagaoka T., Ohmura N., Saiki H., Nagaoka T., Ohmura N., and Saiki H.
- Abstract
The removal of pyritic sulphur from a synthetic mixture of coal and pyrite was investigated using a 50 l cultivation tank and a flotation column 1.5 m high and 80 mm in internal diameter. Thiobacillus ferrooxidans was cultivated for 20 days without precipitating iron compounds. The bacteria were then added to the flotation column at a rate of 7 400 000 000 cells/g coal, with 1 wt% coal slurry fed to the column at a rate of 315 ml/min for 1 h. The sulphur content was reduced from 10.1% in the feed to 1.4% in the froth product, with a combustible coal recovery of 82.7%; in the absence of bacteria, recoveries were 94-99% but there was 7.1% S in the product. For run-of-mine coal from Pittsburgh, Pennsylvania, sulphur was reduced from 2.9% in the feed to 1.2% in the froth product by the addition of 7 700 000 000 cells/g; combustible coal recovery was about 80%., The removal of pyritic sulphur from a synthetic mixture of coal and pyrite was investigated using a 50 l cultivation tank and a flotation column 1.5 m high and 80 mm in internal diameter. Thiobacillus ferrooxidans was cultivated for 20 days without precipitating iron compounds. The bacteria were then added to the flotation column at a rate of 7 400 000 000 cells/g coal, with 1 wt% coal slurry fed to the column at a rate of 315 ml/min for 1 h. The sulphur content was reduced from 10.1% in the feed to 1.4% in the froth product, with a combustible coal recovery of 82.7%; in the absence of bacteria, recoveries were 94-99% but there was 7.1% S in the product. For run-of-mine coal from Pittsburgh, Pennsylvania, sulphur was reduced from 2.9% in the feed to 1.2% in the froth product by the addition of 7 700 000 000 cells/g; combustible coal recovery was about 80%.
23. Effect of physical fitness and training on physiological responses to hypogravity
- Author
-
Saiki, H., primary, Nakaya, M., additional, Sudoh, M., additional, Abe, M., additional, Taketomi, Y., additional, Oh'Ishi, K., additional, Saiki, Y., additional, and Saiki, A., additional
- Published
- 1981
- Full Text
- View/download PDF
24. Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus.
- Author
-
Yutaka Takebe, Carrie J Saucedo, Garry Lund, Rie Uenishi, Saiki Hase, Takayo Tsuchiura, Norman Kneteman, Koreen Ramessar, D Lorne J Tyrrell, Masayuki Shirakura, Takaji Wakita, James B McMahon, and Barry R O'Keefe
- Subjects
Medicine ,Science - Abstract
Hepatitis C virus (HCV) infection is a significant public health problem with over 170,000,000 chronic carriers and infection rates increasing worldwide. Chronic HCV infection is one of the leading causes of hepatocellular carcinoma which was estimated to result in ∼10,000 deaths in the United States in the year 2011. Current treatment options for HCV infection are limited to PEG-ylated interferon alpha (IFN-α), the nucleoside ribavirin and the recently approved HCV protease inhibitors telaprevir and boceprevir. Although showing significantly improved efficacy over the previous therapies, treatment with protease inhibitors has been shown to result in the rapid emergence of drug-resistant virus. Here we report the activity of two proteins, originally isolated from natural product extracts, which demonstrate low or sub-nanomolar in vitro activity against both genotype I and genotype II HCV. These proteins inhibit viral infectivity, binding to the HCV envelope glycoproteins E1 and E2 and block viral entry into human hepatocytes. In addition, we demonstrate that the most potent of these agents, the protein griffithsin, is readily bioavailable after subcutaneous injection and shows significant in vivo efficacy in reducing HCV viral titers in a mouse model system with engrafted human hepatocytes. These results indicate that HCV viral entry inhibitors can be an effective component of anti-HCV therapy and that these proteins should be studied further for their therapeutic potential.
- Published
- 2013
- Full Text
- View/download PDF
25. Isolation and characterization of a replication-competent molecular clone of an HIV-1 circulating recombinant form (CRF33_01B).
- Author
-
Kok Keng Tee, Shigeru Kusagawa, Xiao-Jie Li, Narumi Onogi, Maya Isogai, Saiki Hase, Rie Uenishi, Huanan Liao, Adeeba Kamarulzaman, and Yutaka Takebe
- Subjects
Medicine ,Science - Abstract
A growing number of emerging HIV-1 recombinants classified as circulating recombinant forms (CRFs) have been identified in Southeast Asia in recent years, establishing a molecular diversity of increasing complexity in the region. Here, we constructed a replication-competent HIV-1 clone for CRF33_01B (designated p05MYKL045.1), a newly identified recombinant comprised of CRF01_AE and subtype B. p05MYKL045.1 was reconstituted by cloning of the near full-length HIV-1 sequence from a newly-diagnosed individual presumably infected heterosexually in Kuala Lumpur, Malaysia. The chimeric clone, which contains the 5' LTR (long terminal repeat) region of p93JP-NH1 (a previously isolated CRF01_AE infectious clone), showed robust viral replication in the human peripheral blood mononuclear cells. This clone demonstrated robust viral propagation and profound syncytium formation in CD4+, CXCR4-expressing human glioma NP-2 cells, indicating that p05MYKL045.1 is a CXCR4-using virus. Viral propagation, however, was not detected in various human T cell lines including MT-2, M8166, Sup-T1, H9, Jurkat, Molt-4 and PM1. p05MYKL045.1 appears to proliferate only in restricted host range, suggesting that unknown viral and/or cellular host factors may play a role in viral infectivity and replication in human T cell lines. Availability of a CRF33_01B molecular clone will be useful in facilitating the development of vaccine candidates that match the HIV-1 strains circulating in Southeast Asia.
- Published
- 2009
- Full Text
- View/download PDF
26. Delayed surgical treatment for a traumatic bilateral cervical facet joint dislocation using a posterior-anterior approach: a case report
- Author
-
Shimada Takashi, Ohtori Seiji, Inoue Gen, Nakamura Junichi, Nakada Izumi, Saiki Hiroshi, Chang Song Ho, Kawamura Koui, Takahashi Kazuhisa, and Sugiyama Hiroshi
- Subjects
Medicine - Abstract
Abstract Introduction There have been few reports of patients with bilateral cervical facet dislocations that remain untreated for eight weeks or more. We report the case of a 76-year-old man with an old bilateral cervical facet joint dislocation fracture that was treated by posterior-anterior reduction and fixation. Case presentation A 76-year-old Asian man was involved in a road traffic accident. He presented with neck pain and arm pain on his right side, but motor weakness and paralysis were not observed. He was treated conservatively; however, instability and spondylolisthesis at the C5 to C6 joint increased eight weeks after the injury. We performed a posterior-anterior reduction and fixation. After surgery, bony union was achieved, and his neck pain and arm pain disappeared. Conclusion We recommend reduction and fixation surgery if a patient has an old bilateral facet joint dislocation fracture in the cervical spine.
- Published
- 2013
- Full Text
- View/download PDF
27. Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST.
- Author
-
Nomoto M, Tsuboi Y, Kashihara K, Chiu SW, Maeda T, Saiki H, Watanabe H, Shimo Y, Hattori N, and Yamaguchi T
- Subjects
- Humans, Male, Female, Aged, Japan, Middle Aged, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Levodopa therapeutic use, Levodopa administration & dosage, Drug Prescriptions statistics & numerical data, Dopamine Agonists therapeutic use, Dopamine Agonists administration & dosage, Selegiline therapeutic use, Selegiline administration & dosage, Nitriles therapeutic use, Nitriles administration & dosage, Zonisamide therapeutic use, East Asian People, Catechols, Purines, Parkinson Disease drug therapy, Antiparkinson Agents therapeutic use, Antiparkinson Agents administration & dosage
- Abstract
Background: Non-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson's disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice., Methods: We examined the prescription rates and doses of anti-PD drugs, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) in post hoc analyses of a 52-week observational study of 996 PD patients with wearing-off on levodopa-containing therapy and ≥1 NMS., Results: Dopamine agonists were the most frequently prescribed drugs combined with levodopa-containing drugs, followed by entacapone, zonisamide, istradefylline, selegiline, and amantadine. The daily dose of levodopa-containing drugs, rotigotine, entacapone, istradefylline, and droxidopa, and the levodopa-equivalent dose increased during the observation period. In a subgroup analysis of patients stratified by NMS status (improved/unchanged/deteriorated), the deteriorated group had higher prescription rates of entacapone and istradefylline, whereas the improved group had higher prescription rates of NSAIDs and zonisamide at Week 52. Prescriptions varied by geographical region for anti-PD drugs and by NMS status for NSAIDs., Conclusions: There were significant changes in the prescriptions and dosing of selected anti-PD drugs, especially newer drugs. Anti-PD drug and NSAID prescriptions also varied by changes in NMS status and geographic region., Competing Interests: Masahiro Nomoto reported research funds from Kyowa Kirin in relation to this study; and reported employment by The Social Welfare Organization Imperial Gift Foundation Inc. Saiseikai Imabari Hospital; honoraria from Ehime University, Takeda Pharmaceutical, Kyowa Kirin, Eisai, and Ono Pharmaceutical; consultancies for Kissei Pharmaceutical and SNLD; and has served on advisory boards for the Pharmaceuticals and Medical Devices Agency and Ehime Prefecture. Yoshio Tsuboi reported research funds from Kyowa Kirin in relation to this study; and reported lecture fees from Sumitomo Pharma, Takeda Pharmaceutical, Novartis Pharma, Ono Pharmaceutical, and Eisai; and contributes to courses organized by SUNWELS and Nipro Corporation. Kenichi Kashihara reported research funds from Kyowa Kirin in relation to this study; and reported employment by Okayama Neurology Clinic; and honoraria from Kyowa Kirin, Takeda Pharmaceutical, Ono Pharmaceutical, Sumitomo Pharma, FP Corporation, AbbVie GK, and Eisai. Shih-Wei Chiu reported research funds from Kyowa Kirin in relation to this study. Tetsuya Maeda reported research funds from Kyowa Kirin in relation to this study; and reported lecture fees and scholarship donations from Sumitomo Pharma, Takeda Pharmaceutical Company, Ono Pharmaceutical, Eisai, Otsuka Pharmaceutical, Nippon Boehringer Ingelheim, Daiichi Sankyo, and Japan Medtronic; lecture fees from AbbVie, FP Corporation, Biogen, and Chugai Pharmaceutical; scholarship donations from Bayer Yakuhin, Teijin, and CSL Behring; and consulting fees from Kyowa Kirin and Ono Pharmaceutical. Hidemoto Saiki reported editorial support from Kyowa Kirin in relation to this study; and reported honoraria from Eisai, Sumitomo Pharma, Ono Pharmaceutical, Takeda Pharmaceutical, and Medtronic Japan; and grants from Otsuka Pharmaceutical and PDRadiopharma Inc. Hirohisa Watanabe reported research funds from Kyowa Kirin in relation to this study; and reported honoraria from Takeda Pharmaceutical, AbbVie, Kyowa Kirin, Sumitomo Pharma, Novartis Pharma, Otsuka Pharmaceutical, and FP Corporation. Yasushi Shimo reported honoraria from Takeda Pharmaceutical, Abbott Japan, Otsuka Pharmaceutical, Medtronic Japan, Kyowa Kirin, Eisai, MDS, Boston Scientific Japan, Sumitomo Pharma, Daiichi Sankyo, Nihon Medi-Physics, and EA Pharma; and a grant from Japan Society for the Promotion of Science (JSPS KAKENHI no. 21K07282). Nobutaka Hattori reported research grants, support for attending advisory boards, and support for a joint research department from Kyowa Kirin; and reported research contracts with Sumitomo Pharma and CellSource; consultancy fees from PARKINSON Laboratories; honoraria from Sumitomo Pharma, AbbVie, Otsuka Pharmaceutical, Novartis Pharma, Ono Pharmaceutical, FP Pharmaceutical, Eisai, and Daiichi Sankyo; support for attending advisory boards from Sumitomo Pharma, Novartis Pharma, Ono Pharmaceutical, Teijin Pharma, and Mitsubishi Tanabe Pharma Corporation; support for an endowed department from Nippon Boehringer Ingelheim, FP Pharmaceutical, Teijin Pharma, Fujifilm Wako Pure Chemical Corporation, and Meiji Seika Pharma; support for a joint research department from Kyowa Kirin, Sumitomo Pharma, Parkinson Laboratories, Takeda Pharmaceutical, Otsuka Pharmaceutical, Ono Pharmaceutical, Nihon Medi-Physics, Mitsubishi Tanabe Pharma Corporation, and Sunwels; scholarship donations from FP Pharmaceutical; holds stock in Parkinson Laboratories; honoraria for a team leader role at RIKEN Center for Brain Science; and is a coauthor on patent applications by Juntendo University. Takuhiro Yamaguchi reported grants from Otsuka Pharmaceutical, Solasia Pharma, Japan Tobacco Inc., Daiichi Sankyo, Eisai, and Cordis Corporation; and personal fees from Intellim Corporation, Chugai Pharmaceutical, SONIRE Therapeutics Inc., Merck and Co Inc., EPS Corporation, Japan Tobacco Inc., Ono Pharmaceutical, Kowa Company, Daiichi Sankyo, Eisai, 3H Clinical Trial Inc., and Incyte Biosciences Japan. This does not alter our adherence to PLOS ONE policies on sharing data and materials., (Copyright: © 2024 Nomoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
28. Bleomycin-Induced Pulmonary Fibrosis in Transgenic Mice Carrying the Human MUC5B rs35705950 Variant.
- Author
-
Tharavecharak S, Fujimoto H, Yasuma T, D'Alessandro-Gabazza CN, Toda M, Tomaru A, Saiki H, Uemura M, Kogue Y, Ito T, Furuhashi K, Okano T, Takeshita A, Nishihama K, Ono R, Hataji O, Nosaka T, Kobayashi T, and Gabazza EC
- Subjects
- Animals, Humans, Mice, Pulmonary Fibrosis genetics, Pulmonary Fibrosis pathology, Pulmonary Fibrosis chemically induced, Cytokines metabolism, Cytokines genetics, Lung pathology, Lung metabolism, Idiopathic Pulmonary Fibrosis genetics, Idiopathic Pulmonary Fibrosis pathology, Idiopathic Pulmonary Fibrosis chemically induced, Disease Models, Animal, Bronchoalveolar Lavage Fluid, Bleomycin, Mucin-5B genetics, Mucin-5B metabolism, Mice, Transgenic
- Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive, often fatal lung disease characterized by tissue scarring and declining lung function. The MUC5B promoter polymorphism rs35705950, a significant genetic predisposition for IPF, paradoxically associates with better survival and slower disease progression than other IPF genotypes. This study investigates the potential paradoxical protective effects of this MUC5B variant in lung fibrosis. For this purpose, we developed a transgenic mouse model overexpressing the human MUC5B rs35705950 variant in the proximal large airways. Lung fibrosis was induced through subcutaneous injection of bleomycin. Results demonstrated significantly reduced lung fibrosis severity in transgenic mice compared to wild-type mice, assessed by trichrome staining, Ashcroft scoring, and hydroxyproline levels. Additionally, transgenic mice showed significantly lower levels of inflammatory cells and cytokines (TNFα, IL-6, IFNγ) and growth factors (PDGF, CTGF, IL-13) in the bronchoalveolar lavage fluid and lung tissues. There was also a significant decrease in mRNA expressions of fibrosis-related markers (periostin, fibronectin, Col1a1). In summary, this study reveals that mucin overexpression related to the MUC5B rs35705950 variant in the large airways significantly attenuates lung fibrosis and inflammatory responses in transgenic mice. These findings suggest that the rs35705950 variant modulates inflammatory and fibrotic responses in the proximal airways, which may contribute to the slower disease progression observed in IPF patients carrying this variant. Our study offers a possible explanation for the paradoxical beneficial effects of the MUC5B variant despite its role as a significant predisposing factor for IPF.
- Published
- 2024
- Full Text
- View/download PDF
29. Therapeutic Strategy for Improving Motor Complications of Parkinson's Disease: Short-Term Levodopa-Carbidopa Intestinal Gel Therapy Using a Nasogastric Tube.
- Author
-
Taguchi S, Nakura T, Doyu M, and Saiki H
- Published
- 2024
- Full Text
- View/download PDF
30. Vasospastic angina preceding diagnosis of arrhythmogenic cardiomyopathy in a young athlete.
- Author
-
Sato M, Sato A, Saiki H, Kato K, Ohno S, and Horie M
- Abstract
Competing Interests: All the authors have no conflicts of interest to disclose.
- Published
- 2024
- Full Text
- View/download PDF
31. Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.
- Author
-
Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, Naito M, Kodama S, Furuhashi K, Yagi A, Saiki H, Yasuma T, Okano T, Tomaru A, Tanigawa M, Yoshida M, Hataji O, Ibata H, D'Alessandro-Gabazza CN, Gabazza EC, and Kobayashi T
- Subjects
- Humans, Immune Checkpoint Inhibitors adverse effects, Prognosis, Retrospective Studies, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma drug therapy, Lung Neoplasms
- Abstract
Background: Immune checkpoint inhibitors have recently become the standard of care in the first-line treatment of extensive-stage small cell lung cancer. Although immune-related adverse events have been reported to influence prognosis in non-small cell lung cancer patients, few studies have investigated the prognostic value of immune-related adverse events in small cell lung cancer patients. In this study, we evaluated the prognosis of patients who developed immune-related adverse events after first-line treatment with immune checkpoint inhibitor-based chemotherapy for extensive-stage small cell lung cancer., Methods: We enrolled 90 patients with extensive-stage small cell lung cancer who received immune checkpoint inhibitor-based chemotherapy as first-line treatment from September 2019 to December 2022 in six hospitals in Japan. The patients were categorized into groups with and without immune-related adverse events., Results: There were 23 patients with and 67 without immune-related adverse events. Seventeen patients had grade 1-2 immune-related adverse events, and nine (including overlapping cases) had grade ≥3. The most frequent immune-related adverse event was a skin rash. The median survival time was 22 months in patients with immune-related adverse events and 9.3 months in patients without immune-related adverse events. The hazard ratio was 0.40 (95% confidence interval: 0.19-0.83, p = 0.013)., Conclusions: The results of this study show that immune-related adverse events are associated with improved survival outcomes in patients with extensive-stage small cell lung cancer., (© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
32. Successful Atrial Septal Defect Closure Subsequent to Medical Pulmonary Preconditioning in an Infant With Severe Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia.
- Author
-
Sato M, Saiki H, Saito K, Sato A, Kuwata S, Nakano S, Koizumi J, Oyama K, and Akasaka M
- Abstract
While atrial septal defect (ASD) may contribute to right ventricular decompression in patients with severe pulmonary hypertension (PH), the pulmonary vasculature might be compromised by increased pulmonary blood flow, even though pulmonary vasodilators successfully reduce resistance. ASD closure is a treatment option that may ameliorate PH symptoms associated with bronchopulmonary dysplasia (BPD) in infants. However, the feasibility of ASD closure is obscure in patients with BPD-PH causing right-to-left shunting. Here, we present an eight-month-old girl with ASD complicated by BPD-PH, in which the pulmonary pressure exceeded the systemic pressure; the ASD was successfully closed after pulmonary preconditioning with dexamethasone and high-dose diuretics. Our patient was delivered as the third baby in triplets at a gestational age of 25 weeks, with a birth weight of 344 g. She was diagnosed with BPD at three months of age (37 weeks of postmenstrual age) with a body weight of 1.4 kg. Mild pulmonary hypertension was identified at the age of five months, and oral sildenafil was initiated. While her atrial septal defect was small at the time of PH diagnosis, it became hemodynamically significant when she grew up to 3.4 kg of body weight, at seven months after birth. Her estimated right ventricular pressure was apparently more than the systemic pressure, and oxygen saturation fluctuated between 82% and 97% under oxygen supplementation due to bidirectional interatrial shunt with predominant right-to-left shunting. Pulmonary preconditioning lowered the estimated right ventricular pressure to almost equal the systemic pressure and elevated arterial oxygen saturation while also suppressing right-to-left shunting. Cardiac catheterization after preconditioning revealed a ratio of pulmonary blood pressure to systemic blood pressure ratio (Pp/Ps) of 0.9, pulmonary resistance of 7.3 WU-m
2 , and a pulmonary to systemic blood flow ratio (Qp/Qs) of 1.3 (approximately 1.0 in the normal circulation without significant shunt), with the cardiac index of 2.8 L/min/m2 . The acute pulmonary vasoreactivity test against the combination of 20 ppm nitric oxide and 100% oxygen was negative, although the patient had consistently high pulmonary flow with makeshift improvements after preconditioning. Despite the high pulmonary resistance even after preconditioning, aggressive ASD closure was performed so that pulmonary flow could be consistently suppressed regardless of the pulmonary condition. Her Pp/Ps under 100% oxygen with 20 ppm nitric oxide was 0.7 immediately after closure. After two years of follow-up, her estimated right ventricular pressure was less than half of the systemic pressure with the use of three pulmonary vasodilators, including sildenafil, macitentan, and beraprost. A strategy to temporarily improve PH and respiratory status aimed at ASD closure could be a treatment option for the effective use of multiple pulmonary vasodilators, by which intensive treatment of BPD can be achieved., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2024, Sato et al.)- Published
- 2024
- Full Text
- View/download PDF
33. Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature.
- Author
-
Saiki R, Katayama K, Saiki H, Fukumori A, Tsujimoto K, Yamawaki M, Tanaka F, Takahashi D, Oda K, Suzuki Y, Murata T, and Dohi K
- Subjects
- Male, Humans, Aged, Nivolumab adverse effects, Ipilimumab adverse effects, Immune Checkpoint Inhibitors adverse effects, Nephrotic Syndrome chemically induced, Nephrotic Syndrome drug therapy, Antineoplastic Agents, Immunological adverse effects, Acute Kidney Injury chemically induced, Acute Kidney Injury therapy, Acute Kidney Injury complications, Nephritis, Interstitial chemically induced, Nephritis, Interstitial complications
- Abstract
Background: Recent studies have focused on immune checkpoint inhibitors. Renal complications associated with the use of immune checkpoint inhibitors are uncommon compared with other immune-related adverse events. Acute interstitial nephritis accounts for most of these renal complications, with nephrotic syndrome quite rare. We herein report a case of nephrotic syndrome associated with immune checkpoint inhibitors that was more severe than that in previous cases. By comparing this case with previous reports, the possible reasons for the particular severity of this case are discussed., Case Presentation: A 75-year-old man developed nephrotic syndrome with acute kidney injury after the first combination therapy of nivolumab and ipilimumab for malignant pleural mesothelioma. The results of a kidney biopsy indicated minimal change disease with mild atherosclerosis, acute interstitial nephritis, and fusion of nearly all podocyte foot processes. Nivolumab and ipilimumab therapy were stopped, and treatment with corticosteroids was initiated. We investigated previously reported cases of nephrotic syndrome using immune checkpoint inhibitors. Seventeen cases of immune checkpoint inhibitor-related nephrotic syndrome, including ours, have been reported. Two of the 17 patients with immune checkpoint inhibitor-related nephrotic syndrome required hemodialysis treatment for acute kidney injury. Unlike many previously reported cases, the present patient was administered two different immune checkpoint inhibitors, which may be one of the reasons for the development of severe nephrotic syndrome., Conclusions: In addition to previously reported risk factors, immune checkpoint inhibitor combination therapy can exacerbate nephrotic syndrome compared to immune checkpoint inhibitor monotherapy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
34. Significance of End-Diastolic Forward Flow in Patients With Repaired Tetralogy of Fallot - Its Interaction With the Left Ventricular Property and End Organ Damage.
- Author
-
Takahashi T, Saiki H, Sato A, Kuwata S, Nakano S, Sato Y, Akasaka M, Koizumi J, Senzaki H, and Oyama K
- Subjects
- Humans, Aged, Diastole, Hemodynamics, Vascular Resistance, Ventricular Function, Right, Tetralogy of Fallot, Ventricular Dysfunction, Right complications
- Abstract
Background: Although right ventricular (RV) enlargement may affect RV diastolic dysfunction assessed by end-diastolic forward flow (EDFF) in patients with repaired tetralogy of Fallot (TOF), EDFF may also be modified by left ventricular (LV) hemodynamics. We hypothesized that EDFF is affected by LV hemodynamics, not limited to RV diastolic stiffening., Methods and results: Among 145 consecutive patients with repaired TOF who underwent catheterization, hemodynamic properties in 47 with consistent EDFF and 75 without EDFF were analyzed. Compared with patients without EDFF, those with EDFF had a large RV volume with a high regurgitant fraction. Although cardiac index and central venous pressure (CVP) were similar, contrast injection augmented CVP and LV end-diastolic pressure (EDP) in patients with vs. those without EDFF, suggesting compromised diastolic reserve. In patients with EDFF, the velocity-time integral (VTI) of EDFF was positively correlated with LVEDP and systemic vascular resistance, in addition to RV EDP. EDFF-VTI was correlated with hepatic venous wedge pressure and markers of hepatic dysfunction. Subanalysis of the older (≥6 years) half of the study cohort revealed that EDFF was associated with bi-atrial enlargement independent of RV volume, highlighting the pronounced role of EDFF on the diastolic property in the aged cohort., Conclusions: EDFF-VTI in patients with repaired TOF reflects RV diastolic dysfunction, affected by the left heart system. EDFF-VTI indicates blood stagnation, which may be attributed to end-organ damage.
- Published
- 2023
- Full Text
- View/download PDF
35. Endoscopic submucosal dissection for early gastric cancer in a patient after left ventricular assist device implantation: A case report.
- Author
-
Kuriki S, Tsujii Y, Saiki H, Amano T, Uema R, Kato M, Yoshihara T, Hayashi Y, Hikita H, and Takehara T
- Abstract
The use of left ventricular assist device (LVAD) implantation has increased in recent years. Here, we report the first case of gastric endoscopic submucosal dissection (ESD) following LVAD implantation. A 69-year-old man who previously underwent LVAD implantation for severe heart failure underwent esophagogastroduodenoscopy, which revealed a 15-mm flat-elevated cancerous lesion at the greater curvature of the gastric angle. Before ESD, antithrombotic drugs were discontinued and replaced with 10,000 units of heparin. However, on the second day, the patient experienced dysarthria and right upper-extremity movement disorder despite a prothrombin time/international normalized ratio (PT-INR) of 2.01. On the fifth day, computed tomography revealed a low-density area extending from the left corona radiata to the basal ganglia, leading to a diagnosis of acute cerebral infarction. Aspirin and warfarin were immediately restarted, while the heparin infusion was discontinued after confirming recovery of PT activity. Thereafter, the neurological abnormalities did not aggravate and a trend toward symptomatic improvement was observed. Two months later, ESD was performed under continuous warfarin administration (PT-INR, 2.62) without heparin replacement, and the lesion was curatively resected without complications. The patient was discharged without adverse events. This case report provides useful information on the feasibility and perioperative management of ESD in patients with LVAD., Competing Interests: None., (© 2023 The Authors. DEN Open published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.)
- Published
- 2023
- Full Text
- View/download PDF
36. A novel role for Helicobacter pylori cytotoxin-associated gene A in negative regulation of autophagy in human gastric cells.
- Author
-
Sakatani A, Hayashi Y, Saiki H, Kato M, Uema R, Inoue T, Kimura K, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, and Takehara T
- Subjects
- Humans, Animals, Rats, Cyclooxygenase 2 genetics, Autophagy genetics, Cytotoxins, Inflammation Mediators, Helicobacter pylori, Stomach Neoplasms genetics
- Abstract
Background: Autophagy plays an important role in carcinogenesis and tumor progression in many cancers, including gastric cancer. Cytotoxin-associated gene A (CagA) is a well-known virulent factor in Helicobacter pylori (H. pylori) infection that plays a critical role in gastric inflammation and gastric cancer development. However, its role in autophagy during these processes remains unclear. Therefore, we aimed to clarify the role of CagA in autophagy in CagA-related inflammation., Methods: We evaluated the autophagic index of AGS cells infected with wild-type cagA-positive H. pylori (Hp-WT) and cagA-knockout H. pylori (Hp-ΔcagA) and rat gastric mucosal (RGM1) cells transfected with CagA genes. To identify the mechanisms underlying the down regulation of autophagy in AGS cells infected with H. pylori, we evaluated protein and mRNA expression levels of autophagy core proteins using western blotting and quantitative reverse transcription-polymerase chain reaction (RT-PCR). To determine whether autophagy induced the expression of the pro-inflammatory mediator, cyclooxygenase-2 (COX-2), we evaluated COX-2 expression in AGS cells treated with an autophagy inducer and inhibitor and infected with H. pylori. In addition, we evaluated whether COX-2 protein expression in AGS cells influenced beclin-1 (BECN1) expression with si-RNA transfection when infected with H. pylori., Results: Autophagic flux assay using chloroquine showed that autophagy in AGS cells was significantly suppressed after H. pylori infection. The autophagic index of AGS cells infected with Hp-WT was decreased significantly when compared with that in AGS cells infected with Hp-ΔcagA. The autophagic index of RGM1 cells transfected with CagA was lower, suggesting that CagA inhibits autophagy. In addition, BECN1 expression levels in AGS cells infected with Hp-WT were reduced compared to those in AGS cells infected with Hp-ΔcagA. Furthermore, COX-2 expression in AGS cells infected with H. pylori was controlled in an autophagy-dependent manner. When AGS cells were transfected with small interfering RNA specific for BECN1 and infected with Hp-WT and Hp-ΔcagA, COX-2 was upregulated significantly in cells infected with Hp-ΔcagA., Conclusions: In conclusion, the H. pylori CagA protein negatively regulated autophagy by downregulating BECN1. CagA-induced autophagy inhibition may be a causative factor in promoting pro-inflammatory mediator production in human gastric epithelial cells., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
37. Inclusion body myositis in an older patient following a fall.
- Author
-
Saiki H, Isono H, Ihara K, Kondo K, Isono M, and Shiraoka A
- Abstract
After experiencing a fall, an 82-year-old woman developed progressive loss of lower limb strength and was diagnosed with inclusion body myositis. Although falls and muscle weakness are often regarded as consequences of aging, inclusion body myositis should be considered in a patient with a history of multiple falls., Competing Interests: None declared., (© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
38. Selenium deficiency and scurvy due to an imbalanced diet of snacks and lacto-fermenting drinks: a case report of a 7-year-old boy with autism spectrum disorder.
- Author
-
Okada M, Nagayama Y, Saiki H, Ito K, Yatsuga S, and Nagamitsu S
- Abstract
Background: There have been reports of isolated trace elements or vitamin deficiencies due to imbalanced diets, but no cases of selenium deficiency combined with scurvy have been reported., Case Presentation: A 7 year-old boy diagnosed with autistic spectrum disorder and mild psychomotor retardation, started an imbalanced diet including specific snacks and lacto-fermenting drinks from 5 years of age. Gingival hemorrhage and perioral erosions occurred at 6 years and 8 months of age, and he was referred to our hospital at 7 years of age. Slight tachycardia was found. Serum vitamin C level was 1.1 µg/dL (reference range (rr): 5-17.5 µg/dL), and selenium level was 2.8 µg/dL (rr: 7.7-14.8 µg/dL). He was diagnosed with both selenium deficiency and scurvy. Multivitamins and sodium selenate were administered for 12 days during admission, and symptoms of selenium deficiency and scurvy improved. After discharge, symptoms abated following the administration of multivitamins and regular administration of sodium selenate every 3 months., Conclusions: We report a complicated case of both selenium deficiency and scurvy due to an imbalanced diet of snacks and lacto-fermenting drinks in a 7-year-old boy with autism spectrum disorder. In patients with imbalanced diet, regular blood tests including trace elements and vitamins are necessary., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
39. Chronological T-wave alternation before and after the onset of arrhythmogenic right ventricular cardiomyopathy.
- Author
-
Sato A, Saiki H, Kudo M, Takizawa Y, Kuwata S, Nakano S, Sato Y, Miura K, Oyama K, and Akasaka M
- Subjects
- Child, Humans, Electrocardiography, Arrhythmias, Cardiac, Arrhythmogenic Right Ventricular Dysplasia diagnosis
- Abstract
Identification of arrhythmogenic right ventricular cardiomyopathy (ARVC) during childhood is challenging due to the lack of specific ECG manifestation. We report chronological ECG alteration before several years of the ARVC onset in two affected children. Their ECG at the age of 6 years was almost normal for their age, and their chronological ECGs exhibited inversion of T wave in inferior leads, which are typical for ARVC, developed at younger age than that in precordial leads. In addition, the leftmost T-wave inversion in the precordial lead shifted toward the left in our patients, which is a sharp contrast to its physiological transition., (© 2022 The Authors. Annals of Noninvasive Electrocardiology published by Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
40. Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy.
- Author
-
Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, Naito M, Kodama S, Yagi A, D'Alessandro VF, Yasuma T, Furuhashi K, Saiki H, Okano T, Tomaru A, Tanigawa M, D'Alessandro-Gabazza CN, Gabazza EC, Yoshida M, Hataji O, Ibata H, and Kobayashi T
- Abstract
Adding an immune checkpoint inhibitor to chemotherapy to treat extensive-stage small cell lung cancer is effective. However, there are no reports of an effective second-line treatment in patients previously treated with chemotherapy and immune checkpoint inhibitors as a first-line treatment. Here, we assessed the efficacy and safety of amrubicin as a second-line treatment for extensive-stage small cell lung cancer after chemotherapy and immune checkpoint inhibitor combination therapy. The study enrolled 150 patients with extensive-stage small cell lung cancer. The efficacy and the incidence of adverse events were compared between patients previously treated with immune checkpoint inhibitors and patients without previous immune checkpoint inhibitor treatment. One hundred and twenty-three patients were eligible. There was no difference in objective response rate, time-to-treatment failure, progression-free survival, and overall survival between both groups. The incidence of adverse events was similar in both treatment groups. Pretreatment with immune checkpoint inhibitors was not associated with an increase in amrubicin-related adverse events. This study shows that the efficacy of amrubicin in extensive-stage small cell lung cancer remains unchanged irrespective of previous treatment with immune checkpoint inhibitors. Amrubicin-related adverse events did not increase in patients previously treated with immune checkpoint inhibitors.
- Published
- 2022
- Full Text
- View/download PDF
41. Shear wave dispersion to assess liver disease progression in Fontan-associated liver disease.
- Author
-
Nagasawa T, Kuroda H, Abe T, Saiki H, and Takikawa Y
- Subjects
- Adult, Cross-Sectional Studies, Disease Progression, Fibrosis, Humans, Liver diagnostic imaging, Liver pathology, Liver Cirrhosis complications, Liver Cirrhosis etiology, Postoperative Complications pathology, Prospective Studies, Elasticity Imaging Techniques methods, Liver Diseases complications, Liver Diseases etiology
- Abstract
Aim: We aimed to analyze the dispersion slope (DS) using shear wave dispersion (SWD) in patients with Fontan-associated liver disease (FALD) and to investigate its utility as a biomarker of disease progression., Methods: This cross-sectional study enrolled 27 adults with FALD who underwent SWD, two-dimensional shear wave elastography (2D-SWE), transthoracic echocardiography, cardiac catheterization, or abdominal computed tomography (CT) from April 2019 to April 2021. According to CT findings, patients were divided into two groups: significant fibrosis and non-significant fibrosis., Results: The median DS in the control (n = 10), non-significant fibrosis (n = 12), and significant fibrosis (n = 15) was 9.35, 12.55, and 17.64 (m/s)/kHz, respectively. The significant fibrosis group showed a significantly higher DS than non-significant fibrosis group (P = 0.003). DS showed a significant correlation with central venous pressure (r = 0.532, P = 0.017) and liver stiffness measurements using 2D-SWE (r = 0.581, P = 0.002). The areas under the receiver operating characteristic curve for the diagnosis of significant fibrosis were 0.903 and 0.734 for SWD and 2D-SWE, respectively (P = 0.043)., Conclusions: DS measured by SWD reflects the severity of liver damage in patients with FALD. SWE may be valuable for the therapeutic management of patients with FALD., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
42. Distal arch replacement for aortic aneurysm associated with pseudocoarctation through the L-incision approach.
- Author
-
Goto T, Koizumi J, Saiki H, and Kin H
- Subjects
- Adolescent, Aorta, Thoracic diagnostic imaging, Aorta, Thoracic surgery, Cerebrovascular Circulation, Circulatory Arrest, Deep Hypothermia Induced, Humans, Male, Perfusion, Aortic Aneurysm surgery, Aortic Aneurysm, Thoracic complications, Aortic Aneurysm, Thoracic diagnostic imaging, Aortic Aneurysm, Thoracic surgery, Heart Defects, Congenital
- Abstract
We report the case of a 16-year-old boy in whom we successfully repaired a distal aortic arch aneurysm associated with pseudocoarctation using double aortic cannulation and antegrade selective cerebral perfusion through the L-incision approach. This approach provided excellent exposure from the ascending aorta to the descending aorta, which enabled total body perfusion. We avoided cardiac arrest and hypothermic circulatory arrest during the surgery. The L-incision approach could be a better alternative for aortic arch surgery in adolescents., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.)
- Published
- 2022
- Full Text
- View/download PDF
43. Effect of Minocycline Pleurodesis in Infants With Refractory Chylothorax After Palliative Surgery for Complex Congenital Heart Disease.
- Author
-
Saito K, Saiki H, Tsuchiya S, Takizawa Y, Sato A, Goto T, Toya Y, Matsumoto A, Koizumi J, Oyama K, and Akasaka M
- Abstract
Chylothorax is a critical complication after surgery for congenital heart disease, which markedly compromises the postoperative course with increased mortality. As the cardiovascular load additively causes stagnation of the thoracic duct, chylothorax after palliative cardiac surgery can be highly refractory to the therapies. Here we report a case of two patients with refractory chylothorax attributed to hemodynamic load which was successfully treated with minocycline pleurodesis. In combination with congenital heart disease, extremely low birth weight coupled with prematurity in case 1 and venous obstruction with excessive volume load due to additional aortopulmonary shunt in case 2 additively increased resistance to the therapies, including fasting with total parenteral nutrition (TPN), XIII factor supplementation, octreotide infusion, as well as the use of steroids. As pleural effusion was sustained at more than 50 ml/kg/day, the condition of both patients deteriorated severely; pleurodesis using minocycline was urgently introduced. Pleural effusion declined at every session and both cases were in remission in a few sessions without unfavorable acute reaction. No symptoms suspecting chronic adverse effects were observed during follow-up, including respiratory dysfunction, pulmonary hypertension, tooth staining, or abnormal bone mineralization. Although the application of minocycline for children should be minimized, minocycline pleurodesis can be an option for patients with refractory and life-threatening chylothorax., Competing Interests: The authors have declared financial relationships, which are detailed in the next section., (Copyright © 2022, Saito et al.)
- Published
- 2022
- Full Text
- View/download PDF
44. Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis.
- Author
-
D'Alessandro-Gabazza CN, Yasuma T, Kobayashi T, Toda M, Abdel-Hamid AM, Fujimoto H, Hataji O, Nakahara H, Takeshita A, Nishihama K, Okano T, Saiki H, Okano Y, Tomaru A, Fridman D'Alessandro V, Shiraishi M, Mizoguchi A, Ono R, Ohtsuka J, Fukumura M, Nosaka T, Mi X, Shukla D, Kataoka K, Kondoh Y, Hirose M, Arai T, Inoue Y, Yano Y, Mackie RI, Cann I, and Gabazza EC
- Subjects
- Antibodies, Monoclonal, Bleomycin, Humans, Lung pathology, Peptides pharmacology, Acute Lung Injury pathology, Idiopathic Pulmonary Fibrosis etiology, Microbiota
- Abstract
Idiopathic pulmonary fibrosis is an incurable disease of unknown etiology. Acute exacerbation of idiopathic pulmonary fibrosis is associated with high mortality. Excessive apoptosis of lung epithelial cells occurs in pulmonary fibrosis acute exacerbation. We recently identified corisin, a proapoptotic peptide that triggers acute exacerbation of pulmonary fibrosis. Here, we provide insights into the mechanism underlying the processing and release of corisin. Furthermore, we demonstrate that an anticorisin monoclonal antibody ameliorates lung fibrosis by significantly inhibiting acute exacerbation in the human transforming growth factorβ1 model and acute lung injury in the bleomycin model. By investigating the impact of the anticorisin monoclonal antibody in a general model of acute lung injury, we further unravel the potential of corisin to impact such diseases. These results underscore the role of corisin in the pathogenesis of acute exacerbation of pulmonary fibrosis and acute lung injury and provide a novel approach to treating this incurable disease., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
45. Utility of mass spectrometry and artificial intelligence for differentiating primary lung adenocarcinoma and colorectal metastatic pulmonary tumor.
- Author
-
Shigeeda W, Yosihimura R, Fujita Y, Saiki H, Deguchi H, Tomoyasu M, Kudo S, Kaneko Y, Kanno H, Inoue Y, and Saito H
- Subjects
- Adenocarcinoma of Lung secondary, Aged, Colorectal Neoplasms pathology, Female, Humans, Lung Neoplasms secondary, Male, Adenocarcinoma of Lung diagnosis, Adenocarcinoma of Lung surgery, Artificial Intelligence, Colorectal Neoplasms diagnosis, Lung Neoplasms diagnosis, Lung Neoplasms surgery, Mass Spectrometry methods
- Abstract
Background: Rapid intraoperative diagnosis for unconfirmed pulmonary tumor is extremely important for determining the optimal surgical procedure (lobectomy or sublobar resection). Attempts to diagnose malignant tumors using mass spectrometry (MS) have recently been described. This study evaluated the usefulness of MS and artificial intelligence (AI) for differentiating primary lung adenocarcinoma (PLAC) and colorectal metastatic pulmonary tumor., Methods: Pulmonary samples from 40 patients who underwent pulmonary resection for PLAC (20 tumors, 20 normal lungs) or pulmonary metastases originating from colorectal metastatic pulmonary tumor (CRMPT) (20 tumors, 20 normal lungs) were collected and analyzed retrospectively by probe electrospray ionization-MS. AI using random forest (RF) algorithms was employed to evaluate the accuracy of each combination., Results: The accuracy of the machine learning algorithm applied using RF to distinguish malignant tumor (PLAC or CRMPT) from normal lung was 100%. The algorithms offered 97.2% accuracy in differentiating PLAC and CRMPT., Conclusions: MS combined with an AI system demonstrated high accuracy not only for differentiating cancer from normal tissue, but also for differentiating between PLAC and CRMPT with a short working time. This method shows potential for application as a support tool facilitating rapid intraoperative diagnosis to determine the surgical procedure for pulmonary resection., (© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
46. A Microbiome-Derived Peptide Induces Apoptosis of Cells from Different Tissues.
- Author
-
Saiki H, Okano Y, Yasuma T, Toda M, Takeshita A, Abdel-Hamid AM, Fridman D'Alessandro V, Tsuruga T, D'Alessandro-Gabazza CN, Katayama K, Sugimoto M, Fujimoto H, Yamanaka K, Kobayashi T, Cann I, and Gabazza EC
- Subjects
- Caspase 3 metabolism, Cell Line, Tumor, Epithelial Cells drug effects, Epithelial Cells pathology, HaCaT Cells, Humans, Keratinocytes drug effects, Keratinocytes pathology, Mitochondrial Membranes drug effects, Mitochondrial Membranes metabolism, Podocytes drug effects, Podocytes pathology, Reactive Oxygen Species metabolism, Retina pathology, Transforming Growth Factor beta1 metabolism, Apoptosis drug effects, Microbiota drug effects, Organ Specificity drug effects, Peptides pharmacology
- Abstract
Apoptosis is a programmed cell death involved in embryogenesis and tissue homeostasis under physiological conditions. However, abnormalities in the process of apoptosis are implicated in the pathogenesis of various diseases. The human microbiota may release products that induce apoptosis of host cells. We recently identified a novel microbiome-derived peptide called corisin that worsens lung fibrosis by inducing apoptosis of lung epithelial cells. We hypothesized that corisin and a corisin-like peptide might also induce apoptosis of cells from different tissues. We cultured podocytes, renal tubular epithelial cells, keratinocytes, retinal and intestinal cells treated with corisin and evaluated apoptosis by flow cytometry and Western blotting. Although at different grades, flow cytometry analysis and Western blotting showed that corisin and a corisin-like peptide induced apoptosis of podocytes, keratinocytes, tubular epithelial cells, retinal, and intestinal cells. In addition, we found that corisin synergistically enhances the proapoptotic activity of transforming growth factor-β1 on podocytes. In conclusion, these results suggest that corisin and corisin-like peptides may play a role in the pathogenesis of disease in different organs by promoting apoptosis of parenchymal cells.
- Published
- 2021
- Full Text
- View/download PDF
47. Suppression of autophagy promotes fibroblast activation in p53-deficient colorectal cancer cells.
- Author
-
Inoue T, Hayashi Y, Tsujii Y, Yoshii S, Sakatani A, Kimura K, Uema R, Kato M, Saiki H, Shinzaki S, Iijima H, and Takehara T
- Subjects
- Autophagy-Related Proteins metabolism, Biomarkers, Tumor, Cell Line, Tumor, Cells, Cultured, Coculture Techniques, Colorectal Neoplasms pathology, Exosomes metabolism, Gene Expression Regulation, Neoplastic, HCT116 Cells, Humans, MicroRNAs genetics, Models, Biological, Tumor Microenvironment genetics, Vesicular Transport Proteins metabolism, Autophagy genetics, Cancer-Associated Fibroblasts metabolism, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Tumor Suppressor Protein p53 deficiency
- Abstract
Deficiency of p53 in cancer cells activates the transformation of normal tissue fibroblasts into carcinoma-associated fibroblasts; this promotes tumor progression through a variety of mechanisms in the tumor microenvironment. The role of autophagy in carcinoma-associated fibroblasts in tumor progression has not been elucidated. We aimed to clarify the significance of autophagy in fibroblasts, focusing on the TP53 status in co-cultured human colorectal cancer cell lines (TP53-wild-type colon cancer, HCT116; TP53-mutant colon cancer, HT29; fibroblast, CCD-18Co) in vitro. Autophagy in fibroblasts was significantly suppressed in association with ACTA2, CXCL12, TGFβ1, VEGFA, FGF2, and PDGFRA mRNA levels, when co-cultured with p53-deficient HCT116
sh p53 cells. Exosomes isolated from the culture media of HCT116sh p53 cells significantly suppressed autophagy in fibroblasts via inhibition of ATG2B. Exosomes derived from TP53-mutant HT29 cells also suppressed autophagy in fibroblasts. miR-4534, extracted from the exosomes of HCT116sh p53 cells, suppressed ATG2B in fibroblasts. In conclusion, a loss of p53 function in colon cancer cells promotes the activation of surrounding fibroblasts through the suppression of autophagy. Exosomal miRNAs derived from cancer cells may play a pivotal role in the suppression of autophagy., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
48. Echocardiogram Unmasked Hemodynamic Advantage of Atrial Pacing in Securing Ventricular Preload in a Fontan Patient with Junctional Rhythm.
- Author
-
Saiki H, Kawada K, Kuwata S, Takanashi M, Fukunishi T, Miyaji K, and Senzaki H
- Subjects
- Echocardiography, Electrocardiography, Heart Atria diagnostic imaging, Heart Defects, Congenital physiopathology, Heart Ventricles diagnostic imaging, Humans, Infant, Male, Cardiac Pacing, Artificial, Fontan Procedure methods, Heart Atria physiopathology, Heart Defects, Congenital therapy, Heart Ventricles physiopathology, Hemodynamics physiology
- Abstract
While the advancement of perioperative management has expanded Fontan candidacy, not all patients have a successful postoperative course. Our case was a right isomerism patient who could not leave the ICU due to high central venous pressure and low output syndrome. Initial observation of the monitor ECG showed his rhythm to be supraventricular, however, an echocardiogram indicated simultaneous contraction of the atrium and ventricle, implying a junctional rhythm. While neither central venous pressure nor blood pressure improved with temporary pacing, better central venous and pulmonary venous blood flow patterns during pacing unraveled its positive impact. The patient successfully left the ICU after permanent pacing implantation. Hemodynamic study revealed a beneficial impact of atrial pacing in securing cardiac output and ventricular preload, lowering central venous pressure, and shortening blood transit time, which is partly attributed to the optimization of the fenestration function in reservation of the preload. Our case emphasizes the significant advantage of atrial pacing in a failing Fontan patient with junctional rhythm by reducing venous congestion and maximizing the benefit of fenestration.
- Published
- 2021
- Full Text
- View/download PDF
49. Venous Properties in a Fontan Patient with Successful Remission of Protein-Losing Enteropathy.
- Author
-
Kuwata S, Saiki H, Takanashi M, Fukunishi T, Miyaji K, and Senzaki H
- Subjects
- Hemodynamics physiology, Humans, Hypoplastic Left Heart Syndrome diagnosis, Hypoplastic Left Heart Syndrome surgery, Infant, Male, Postoperative Complications physiopathology, Protein-Losing Enteropathies physiopathology, Pulmonary Valve Stenosis physiopathology, Remission, Spontaneous, Central Venous Pressure physiology, Fontan Procedure adverse effects, Protein-Losing Enteropathies complications, Pulmonary Valve Stenosis etiology
- Abstract
We present the case of a 1-year-old boy who developed protein-losing enteropathy (PLE) within 2 months of a fenestrated Fontan procedure. His fenestration rapidly closed despite bilateral pulmonary stenosis (BPS). Subsequent to PLE onset, both fenestration and the bilateral pulmonary artery were reconstructed, and the patient's PLE had been in remission, with additive use of medications, for more than 2 years. Notably, although fenestration closed again and central venous pressure (CVP) reduction was minimal, the surrogates of venous return resistance were markedly suppressed as shown by increased blood volume, reduced estimated mean circulatory filling pressure, and suppressed CVP augmentation against a contrast agent. Taken together, dynamic characteristics of venous stagnation, rather than the absolute value of CVP, were ameliorated by the pulmonary reconstruction and use of medications, suggesting a significant role of venous property in the physiology of PLE. In addition, simultaneous measures of CVP and ventricular end-diastolic pressure during the abdominal compression procedure suggested a limited therapeutic role of fenestration against PLE in this patient.
- Published
- 2021
- Full Text
- View/download PDF
50. Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis.
- Author
-
Okano T, Kobayashi T, Yasuma T, D'Alessandro-Gabazza CN, Toda M, Fujimoto H, Nakahara H, Okano Y, Takeshita A, Nishihama K, Saiki H, Tomaru A, Fridman D'Alessandro V, Ishida S, Sugimoto H, Takei Y, and Gabazza EC
- Abstract
Idiopathic pulmonary fibrosis is a chronic, progressive, and lethal lung disease of unknown etiology. Antifibrotic drugs, including pirfenidone, are currently used for the treatment of the disease. The oral administration of pirfenidone is an effective therapy, as demonstrated by several clinical trials, although it causes severe adverse events in some patients. We hypothesized that low-dose intrapulmonary delivery of pirfenidone is effective in human transforming growth factorβ1-driven pulmonary fibrosis. To demonstrate our hypothesis, we compared the therapeutic efficacy of varying doses of pirfenidone administered by oral and intranasal routes in a human transforming growth factor-β1 transgenic mouse with established pulmonary fibrosis. We found similar amelioration of lung cell infiltration, inflammatory and fibrotic cytokines, lung fibrosis score, and hydroxyproline content in mice with human transforming growth factor-β1-mediated pulmonary fibrosis treated with low-dose intranasal pirfenidone and high-dose oral pirfenidone. This study showed that pirfenidone is a potent inhibitor of human transforming growth factor-β1-driven lung fibrosis and that intrapulmonary delivery of low-dose pirfenidone produces therapeutic responses equivalent to high-dose of oral pirfenidone., Competing Interests: ECG, CND-G, and TY have received a grant from Shionogi Co. to support in part the execution of the experimental study reported in the present manuscript, and SI and HS are employees from Shionogi & Co., Ltd. ECG and TK have a patent on the mouse used in this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2020 Okano, Kobayashi, Yasuma, D'alessandro-Gabazza, Toda, Fujimoto, Nakahara, Okano, Takeshita, Nishihama, Tomaru, Fridman D'alessandro, Ishida, Sugimoto, Takei and Gabazza.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.